- Home
- XAIR vs BRTX Comparison
XAIR vs BRTX Comparison
Compare XAIR & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | BRTX |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.3M |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | XAIR | BRTX |
|---|---|---|
| Price | $0.50 | $0.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 336.8K | ★ 1.1M |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,705,000.00 | $81,000.00 |
| Revenue This Year | $122.00 | $298.39 |
| Revenue Next Year | $58.15 | $64.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.19 |
| 52 Week High | $3.78 | $2.04 |
Technical Indicators
Market Signals| Indicator | XAIR | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 34.02 |
| Support Level | $0.43 | $0.19 |
| Resistance Level | $0.82 | $0.32 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 17.29 | 9.33 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.